{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:28Z","timestamp":1740120088433,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12185-020-02934-6","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T16:03:38Z","timestamp":1598889818000},"page":"466-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients"],"prefix":"10.1007","volume":"112","author":[{"given":"Ken","family":"Ishiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yonemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyoshi","family":"Noji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Rottinghaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha","family":"Aguzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yokosawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzuru","family":"Kanakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"2934_CR1","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. https:\/\/doi.org\/10.1038\/nrdp.2017.28.","journal-title":"Nat Rev Dis Primers"},{"key":"2934_CR2","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804\u201311. https:\/\/doi.org\/10.1182\/blood-2014-02-522128.","journal-title":"Blood"},{"key":"2934_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.md.0000126763.68170.46","volume":"83","author":"J Nishimura","year":"2004","unstructured":"Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193\u2013207. https:\/\/doi.org\/10.1097\/01.md.0000126763.68170.46.","journal-title":"Medicine (Baltimore)"},{"key":"2934_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12185-019-02699-7","volume":"110","author":"M Sakurai","year":"2019","unstructured":"Sakurai M, Jang JH, Chou WC, Kim JS, Wilson A, Nishimura JI, et al. Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2019;110:411\u20138. https:\/\/doi.org\/10.1007\/s12185-019-02699-7.","journal-title":"Int J Hematol"},{"key":"2934_CR5","unstructured":"Soliris [prescribing information]. Alexion Pharmaceuticals, Inc.: New Haven, CT; 2019."},{"key":"2934_CR6","unstructured":"Soliris [summary of product characteristics]. Alexion Europe SAS: Paris, France; 2017."},{"key":"2934_CR7","unstructured":"Alexion accelerates plans to launch Soliris\u00ae (eculizumab) in Japan [news release]. Cheshire, CN: Alexion Pharmaceuticals, Inc. June 2, 2010. https:\/\/ir.alexion.com\/news-releases\/news-release-details\/alexion-accelerates-plans-launch-solirisr-eculizumab-japan. Accessed 14 Aug 2020."},{"key":"2934_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233\u201343. https:\/\/doi.org\/10.1056\/NEJMoa061648.","journal-title":"N Engl J Med"},{"key":"2934_CR9","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840\u20137. https:\/\/doi.org\/10.1182\/blood-2007-06-094136.","journal-title":"Blood"},{"key":"2934_CR10","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","volume":"110","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123\u20138. https:\/\/doi.org\/10.1182\/blood-2007-06-095646.","journal-title":"Blood"},{"key":"2934_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ajh.24278","volume":"91","author":"M Loschi","year":"2016","unstructured":"Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, et al. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol. 2016;91:366\u201370. https:\/\/doi.org\/10.1002\/ajh.24278.","journal-title":"Am J Hematol"},{"key":"2934_CR12","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786\u201392. https:\/\/doi.org\/10.1182\/blood-2011-02-333997.","journal-title":"Blood"},{"key":"2934_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62\u201373. https:\/\/doi.org\/10.1111\/bjh.12347.","journal-title":"Br J Haematol"},{"key":"2934_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s12185-013-1346-4","volume":"97","author":"JW Lee","year":"2013","unstructured":"Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013;97:749\u201357. https:\/\/doi.org\/10.1007\/s12185-013-1346-4.","journal-title":"Int J Hematol"},{"key":"2934_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bcmd.2017.03.013","volume":"65","author":"MN Yenerel","year":"2017","unstructured":"Yenerel MN, Muus P, Wilson A, Szer J. Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. Blood Cells Mol Dis. 2017;65:29\u201334. https:\/\/doi.org\/10.1016\/j.bcmd.2017.03.013.","journal-title":"Blood Cells Mol Dis"},{"key":"2934_CR16","unstructured":"Ultomiris [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; 2018."},{"key":"2934_CR17","unstructured":"Brazilian Health Authority. Ultomiris approval Brazil. In: Brazilian Health Authority Diario Oficial da Uniao (Suplemento), No. 169, September 2, 2019:46-47. ISSN 1677-7042."},{"key":"2934_CR18","unstructured":"Health Canada. Ultomiris approval Canada: Health Canada; 2019. https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?linkID=RDS00547. Accessed 14 Aug 2020."},{"key":"2934_CR19","unstructured":"Ultomiris\u00ae (ravulizumab) receives marketing authorization from European commission for adults with paroxysmal nocturnal hemoglobinuria (PNH) [press release]. Boston, MA: Alexion Pharmaceuticals, Inc. July 3, 2019. https:\/\/www.biospace.com\/article\/ultomiris-ravulizumab-receives-marketing-authorization-from-european-commission-for-adults-with-paroxysmal-nocturnal-hemoglobinuria-pnh-\/. Accessed 14 Aug 2020."},{"key":"2934_CR20","unstructured":"Australian Product Information\u2014Ultomiris (Ravulizumab RCH) Concentrated Solution for Intravenous Infusion. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-ravulizumab-191113-pi.pdf. Published 13 Nov 2019. Accessed 4 Feb 2020."},{"key":"2934_CR21","doi-asserted-by":"crossref","unstructured":"Sahelijo L, Mujeebuddin A, Mitchell D, Larouche R, Yu Z-X, Zhang Y, et al. First in human single-ascending dose study: safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervals. Blood. 2015;126(23) (Abstract 4777)","DOI":"10.1182\/blood.V126.23.4777.4777"},{"key":"2934_CR22","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","volume":"2","author":"A Roth","year":"2018","unstructured":"Roth A, Rottinghaus ST, Hill A, Bachman ES, Kim JS, Schrezenmeier H, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies. Blood Adv. 2018;2:2176\u201385. https:\/\/doi.org\/10.1182\/bloodadvances.2018020644.","journal-title":"Blood Adv"},{"key":"2934_CR23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, de Fontbrune Sicre F, Wong Lee L, Pessoa V, Gualandro S, Fureder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133:530\u20139. https:\/\/doi.org\/10.1182\/blood-2018-09-876136.","journal-title":"Blood"},{"key":"2934_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133:540\u20139. https:\/\/doi.org\/10.1182\/blood-2018-09-876805.","journal-title":"Blood"},{"key":"2934_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","volume":"93","author":"Y Kanakura","year":"2011","unstructured":"Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93:36\u201346. https:\/\/doi.org\/10.1007\/s12185-010-0748-9.","journal-title":"Int J Hematol"},{"key":"2934_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12185-016-2065-4","volume":"104","author":"H Ninomiya","year":"2016","unstructured":"Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104:548\u201358. https:\/\/doi.org\/10.1007\/s12185-016-2065-4.","journal-title":"Int J Hematol"},{"key":"2934_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s12185-018-2409-3","volume":"107","author":"Y Ueda","year":"2018","unstructured":"Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, et al. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2018;107:656\u201365. https:\/\/doi.org\/10.1007\/s12185-018-2409-3.","journal-title":"Int J Hematol"},{"key":"2934_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370:632\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1311084.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02934-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02934-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02934-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T23:43:13Z","timestamp":1630366993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02934-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2934"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02934-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was funded by Alexion Pharmaceuticals, Inc., Boston, MA, USA. Ken Ishiyama has received research funding from Alexion Pharma G. K. Shinji Nakao has received honoraria from Alexion Pharmaceuticals, Inc. Kensuke Usuki has received honoraria and speakers bureau fees from Alexion Pharmaceuticals, Inc. Yuji Yonemura has received honoraria and research funding from Alexion Pharmaceuticals, Inc. Shin-ichiro Fujiwara has received personal fees from Alexion Pharma G. K. Scott Rottinghaus and Rasha Aguzzi are employees and stockholders of Alexion Pharmaceuticals, Inc. Jun Yokosawa is an employee of Alexion Pharma G. K. and owns stock\/stock options in the company. Jun-Ichi Nishimura has received grants and personal fees from Alexion Pharma G. K. Yuzuru Kanakura has received grants from Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceuticals, Eisai, Janssen Pharmaceuticals K. K., the Japan Blood Products Organization, Kyowa Hakko Kirin Pharmaceuticals, Nippon Shinyaku, Novartis Pharma K. K., Ono Pharmaceuticals, Pfizer, Shionogi Pharmaceuticals, Taiho Pharmaceuticals, Takeda Pharmaceuticals, and Teijin Pharma. Shinichiro Okamoto has received honoraria and research funding from Alexion Pharma G. K. Takayuki Ikezoe, Michihiro Uchiyama, Yasuo Mori, Tetsuya Fukuda, Masaya Okada, and Hideyoshi Noji have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The protocol was approved by the institutional review board and the designs of both studies were approved by local ethics committees and trials were conducted in accordance with the principles of the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval"}}]}}